Impact of the COVID-19 Pandemic on Inpatient Antibiotic Use in the United States, January 2019 Through July 2022

Erin N O'Leary; Melinda M Neuhauser; Arjun Srinivasan; Heather Dubendris; Amy K Webb; Minn M Soe; Lauri A Hicks; Hsiu Wu; Sarah Kabbani; Jonathan R Edwards

doi:10.1093/cid/ciad453

Impact of the COVID-19 Pandemic on Inpatient Antibiotic Use in the United States, January 2019 Through July 2022

Clin Infect Dis. 2024 Jan 25;78(1):24-26. doi: 10.1093/cid/ciad453.

Authors

Erin N O'Leary^{1

2}, Melinda M Neuhauser¹, Arjun Srinivasan¹, Heather Dubendris^{1

2}, Amy K Webb^{1

2}, Minn M Soe¹, Lauri A Hicks¹, Hsiu Wu¹, Sarah Kabbani¹, Jonathan R Edwards¹

Affiliations

¹ Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
² Lantana Consulting Group, Inc, Thetford, Vermont, USA.

PMID: 37536269
DOI: 10.1093/cid/ciad453

Abstract

Antimicrobial use data reported to the National Healthcare Safety Network's Antimicrobial Use and Resistance Module between January 2019 and July 2022 were analyzed to assess the impact of the COVID-19 pandemic on inpatient antimicrobial use.

Keywords: COVID-19; National Healthcare Safety Network; antibiotic stewardship; antibiotic use; hospital epidemiology.

Published by Oxford University Press on behalf of Infectious Diseases Society of America 2023.

MeSH terms

Anti-Bacterial Agents / therapeutic use
Anti-Infective Agents*
COVID-19*
Humans
Inpatients
Pandemics
United States / epidemiology

Substances

Anti-Bacterial Agents
Anti-Infective Agents